Single Nucleotide Polymorphisms Associated with Prostate Cancer Progression: A Systematic Review.

IF 1.8 4区医学 Q3 ONCOLOGY

Cancer Investigation Pub Date : 2024-01-01 Epub Date: 2023-12-18 DOI:10.1080/07357907.2023.2291776

Daniel Felipe Mendivelso González, Santiago Andrés Sánchez Villalobos, Andrea Estefanía Ramos, Wendy Johana Montero Ovalle, Martha Lucía Serrano López

{"title":"Single Nucleotide Polymorphisms Associated with Prostate Cancer Progression: A Systematic Review.","authors":"Daniel Felipe Mendivelso González, Santiago Andrés Sánchez Villalobos, Andrea Estefanía Ramos, Wendy Johana Montero Ovalle, Martha Lucía Serrano López","doi":"10.1080/07357907.2023.2291776","DOIUrl":null,"url":null,"abstract":"Background: New biomarkers of progression in patients with prostate cancer (PCa) are needed to improve their classification and clinical management. This systematic review investigated the relationship between single nucleotide polymorphisms (SNPs) and PCa progression.Methods: A keyword search was performed in Pubmed, EMBASE, Scopus, Web of Science, and Cochrane for publications between 2007 and 2022. We included articles with adjusted and significant associations, a median follow-up greater than or equal to 24 months, patients taken to radical prostatectomy (RP) as a first therapeutic option, and results presented based on biochemical recurrence (BCR).Results: In the 27 articles selected, 73 SNPs were identified in 39 genes, organized in seven functional groups. Of these, 50 and 23 SNPs were significantly associated with a higher and lower risk of PCa progression, respectively. Likewise, four haplotypes were found to have a significant association with PCa progression.Conclusion: This article highlights the importance of SNPs as potential markers of PCa progression and their possible functional relationship with some genes relevant to its development and progression. However, most variants were identified only in cohorts from two countries; no additional studies reproduce these findings.","PeriodicalId":9463,"journal":{"name":"Cancer Investigation","volume":" ","pages":"75-96"},"PeriodicalIF":1.8000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer Investigation","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/07357907.2023.2291776","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/12/18 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: New biomarkers of progression in patients with prostate cancer (PCa) are needed to improve their classification and clinical management. This systematic review investigated the relationship between single nucleotide polymorphisms (SNPs) and PCa progression.

Methods: A keyword search was performed in Pubmed, EMBASE, Scopus, Web of Science, and Cochrane for publications between 2007 and 2022. We included articles with adjusted and significant associations, a median follow-up greater than or equal to 24 months, patients taken to radical prostatectomy (RP) as a first therapeutic option, and results presented based on biochemical recurrence (BCR).

Results: In the 27 articles selected, 73 SNPs were identified in 39 genes, organized in seven functional groups. Of these, 50 and 23 SNPs were significantly associated with a higher and lower risk of PCa progression, respectively. Likewise, four haplotypes were found to have a significant association with PCa progression.

Conclusion: This article highlights the importance of SNPs as potential markers of PCa progression and their possible functional relationship with some genes relevant to its development and progression. However, most variants were identified only in cohorts from two countries; no additional studies reproduce these findings.

查看原文本刊更多论文

与前列腺癌进展相关的单核苷酸多态性：系统综述。

背景：前列腺癌（PCa）患者的病情进展需要新的生物标志物来改进分类和临床治疗。本系统综述研究了单核苷酸多态性（SNPs）与 PCa 进展之间的关系：在 Pubmed、EMBASE、Scopus、Web of Science 和 Cochrane 中对 2007 年至 2022 年间的出版物进行了关键词检索。我们纳入了调整后具有显著关联、中位随访时间大于或等于24个月、将根治性前列腺切除术（RP）作为首选治疗方案的患者，以及根据生化复发（BCR）得出结果的文章：在所选的 27 篇文章中，在 39 个基因中发现了 73 个 SNPs，分为 7 个功能组。其中，分别有 50 个和 23 个 SNP 与 PCa 进展的较高风险和较低风险显著相关。同样，还发现 4 个单倍型与 PCa 进展有显著相关性：本文强调了 SNPs 作为 PCa 进展潜在标志物的重要性，以及它们与 PCa 发展和进展相关基因之间可能存在的功能关系。然而，大多数变异仅在两个国家的队列中发现；没有其他研究再现这些发现。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Cancer Investigation 医学-肿瘤学

CiteScore

3.80

自引率

4.20%

发文量

审稿时长

8.5 months

期刊介绍： Cancer Investigation is one of the most highly regarded and recognized journals in the field of basic and clinical oncology. It is designed to give physicians a comprehensive resource on the current state of progress in the cancer field as well as a broad background of reliable information necessary for effective decision making. In addition to presenting original papers of fundamental significance, it also publishes reviews, essays, specialized presentations of controversies, considerations of new technologies and their applications to specific laboratory problems, discussions of public issues, miniseries on major topics, new and experimental drugs and therapies, and an innovative letters to the editor section. One of the unique features of the journal is its departmentalized editorial sections reporting on more than 30 subject categories covering the broad spectrum of specialized areas that together comprise the field of oncology. Edited by leading physicians and research scientists, these sections make Cancer Investigation the prime resource for clinicians seeking to make sense of the sometimes-overwhelming amount of information available throughout the field. In addition to its peer-reviewed clinical research, the journal also features translational studies that bridge the gap between the laboratory and the clinic.